4D Molecular Therapeutics, Inc. Ratios

Ratios Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Profitability
EBT Margin -705.12%-415.16%-394.70%-3,434.29%-485.72%-434,570.27%
EBIT Margin -726.65%-416.28%-395.46%-3,516.52%-544.65%-507,678.38%
EBITDA Margin -726.65%-416.28%-395.46%-3,516.52%-544.65%-507,678.38%
Operating Margin -726.65%-416.28%-395.46%-3,516.52%-544.65%-507,678.38%
Net Margin -705.78%-416.49%-395.37%-3,435.41%-486.59%-434,778.38%
FCF Margin -571.34%-381.35%-433.77%-3,139.05%-379.11%-373,975.68%
Efficiency
Assets Average 173.28M320.91M307.67M300.87M450.14M
Equity Average 91.71M287.75M275.22M269.58M409.22M
Invested Capital -72.97M256.39M319.11M231.34M307.83M510.61M
Asset Utilization Ratio 0.080.060.010.070.00
Leverage & Solvency
Equity Ratio -1.250.890.900.880.910.91
Valuation
Enterprise Value -49.65M711.18M457.35M505.88M577.96M-167.39M
Market Capitalization 987.91M705.13M719.43M866.19M257.49M
Return Ratios
Return on Sales -7.05%-4.15%-3.95%-34.34%-4.86%
Return on Capital Employed -0.36%-0.23%-0.38%-0.40%-0.45%
Return on Assets -0.33%-0.22%-0.35%-0.33%-0.36%
Return on Equity -0.62%-0.25%-0.39%-0.37%-0.39%